Alberto Garaventa
Overview
Explore the profile of Alberto Garaventa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
3265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lopci E, Elia C, Catalfamo B, Burnelli R, De Re V, Mussolin L, et al.
J Clin Med
. 2022 Oct;
11(20).
PMID: 36294544
Rationale: Therapy response evaluation by 18F-fluorodeoxyglucose PET/CT (FDG PET) has become a powerful tool for the discrimination of responders from non-responders in pediatric Hodgkin lymphoma (HL). Recently, volumetric analyses have...
12.
Pastorino F, Capasso M, Brignole C, Giglio S, Bensa V, Cantalupo S, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232538
Neuroblastoma (NB) is the most common extracranial solid tumor encountered in childhood. Although there has been significant improvement in the outcomes of patients with high-risk disease, the prognosis for patients...
13.
Bottino C, Della Chiesa M, Sorrentino S, Morini M, Vitale C, Dondero A, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230485
High-risk neuroblastomas (HR-NB) still have an unacceptable 5-year overall survival despite the aggressive therapy. This includes standardized immunotherapy combining autologous hemopoietic stem cell transplantation (HSCT) and the anti-GD2 mAb. The...
14.
Cangelosi D, Brignole C, Bensa V, Tamma R, Malaguti F, Carlini B, et al.
EBioMedicine
. 2022 Oct;
85:104300.
PMID: 36209521
Background: Neuroblastoma (NB) represents the most frequent form of extra-cranial solid tumour of infants, responsible for 15% of childhood cancer deaths. Nucleolin (NCL) prognostic value in NB was investigated. Methods:...
15.
Fiz F, Bottoni G, Bini F, Cerroni F, Marinozzi F, Conte M, et al.
Pediatr Blood Cancer
. 2022 Aug;
69(11):e29910.
PMID: 35920594
Purpose: To evaluate the prognostic value of texture analysis of the primary tumour with fluorine-dihydroxyphenylalanine positron emission tomography/X-ray computed tomography ( F-DOPA PET/CT) in patients affected by high-risk neuroblastoma (HR-NBL)....
16.
Barco S, Lavarello C, Cangelosi D, Morini M, Eva A, Oneto L, et al.
Front Oncol
. 2022 Jun;
12:845936.
PMID: 35756625
Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the survival rate of NB has improved over the years, the outcome of NB still remains poor for...
17.
Massano D, Carraro E, Mussolin L, Buffardi S, Barat V, Zama D, et al.
Pediatr Blood Cancer
. 2022 Jun;
69(10):e29801.
PMID: 35656841
Background: Brentuximab vedotin (BV) is an antibody drug-conjugated anti-CD30 approved for the treatment of adult classical Hodgkin's lymphoma (HL), whereas it is considered as off-label indication in paediatrics. The aim...
18.
Morabito L, Allegri A, Capra A, Capasso M, Capra V, Garaventa A, et al.
Genes (Basel)
. 2022 Apr;
13(4).
PMID: 35456387
Osteogenesis imperfecta/Ehlers−Danlos (OI/EDS) overlap syndrome is a recently described disorder of connective tissue, characterized by mutation of COL1A1 (17q21.33) or COL1A2 (7q21.3) genes, that are involved in α-1 and α-2...
19.
Wieczorek A, Manzitti C, Garaventa A, Gray J, Papadakis V, Valteau-Couanet D, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454826
Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome of patients enrolled in two prospective clinical trials who...
20.
Garaventa A, Parodi S, Guerrini G, Farruggia P, Sala A, Pillon M, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326622
The objective of this study was to identify prognostic factors for children and adolescents with relapsed or progressive classical Hodgkin’s lymphoma (cHL) to design salvage therapy tailored to them. We...